TNNT2 and amyotrophic lateral sclerosis: cTnT was analyzed at baseline and during tofersen treatment in 23 SOD1‐ALS patients at two specialized ALS centers in Germany and compared to a control cohort of 74 ALS patients without SOD1 variants.